Search clinical trials for: PD-0332991

Total 1175 results

National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
University of California, San Francisco
Pfizer

Terminated

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma (PD0332991)

Glioblastoma | Gliosarcoma | Anaplastic Astrocytoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm

United States
Roswell Park Cancer Institute

Withdrawn

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

Malignant Solid Neoplasm | Lung Adenocarcinoma | Colorectal Carcinoma | Pancreatic Carcinoma

United States
Emory University
National Cancer Institute (NCI)

Withdrawn

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Breast Carcinoma | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

CCND1 Gene Amplification | CCND2 Gene Amplification | CCND3 Gene Amplification | CDK4 Gene Amplification | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Recurrent Childhood Medulloblastoma | Childhood Choroid Plexus Tumor | Childhood Ependymoblastoma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Childhood Medulloepithelioma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent... and other conditions

United States
Pfizer

Completed

A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)

Healthy

United Kingdom
M.D. Anderson Cancer Center

Completed

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Unresectable Carcinoma

United States
Dana-Farber Cancer Institute
Pfizer

Completed

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Breast Cancer

United States
Dana-Farber Cancer Institute

Completed

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Solid Tumors | KRAS Mutant Non-Small Cell Lung Cancer

United States
Pfizer

Completed

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

Healthy

United States
Pfizer

Completed

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

Healthy

United States
Pamela Munster
Pfizer; Xynomic Pharmaceuticals, Inc.

Withdrawn

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
Institut Bergonié

Completed

Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (CYCLIGIST)

Advanced Gastrointestinal Stromal Tumors

France
UNC Lineberger Comprehensive Cancer Center
Pfizer

Terminated

Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

Metastatic Urothelial Carcinoma (UC)

United States
Pfizer

Completed

A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Neoplasms | Lymphoma, Non-Hodgkin

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Pfizer

Active, not recruiting

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

HCC | Advanced Hepatocellular Carcinoma | Liver Cancer

United States
Pfizer

Completed

A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male Volunteers

Healthy

United States
Pfizer

Completed

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

Healthy

United States
Pfizer

Completed

An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

Lymphoma, Mantle-Cell

United States
University of Ulm
Pfizer; National Center for Tumor Diseases, Heidelberg

Unknown

Study of Palbociclib in MLL-rearranged Acute Leukemias

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

Germany
Pfizer

Completed

Relative Bioavailability Study

Healthy

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma (OPTIMUM)

Melanoma BRAF V600E/K Mutated | CDNKN2A Loss Defined

France
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Metastatic Breast Carcinoma

United States
University of Texas Southwestern Medical Center
University of Pennsylvania; Pfizer

Completed

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

Advanced Breast Cancer

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Adult Solid Tumor | HER2-positive Breast Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Stage IV Ovarian Germ Cell Tumor | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative... and other conditions

United States
German Breast Group
Pfizer; AGO Study Group; Breast International Group; NSABP Foundation Inc

Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B)

Breast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG Score

United States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | HER2/Neu Negative | Estrogen Receptor and/or Progesterone Receptor Positive

United States
National Cancer Institute (NCI)

Withdrawn

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma

United States
Jules Bordet Institute

Completed

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA) (NeoRHEA)

Breast Cancer Female

Belgium
Sidney Kimmel Comprehensive Cancer Center at Johns...
Pfizer; The Leukemia and Lymphoma Society

Terminated

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

Refractory Acute Leukemia | Relapsed Acute Leukemia | High-Risk Myelodysplasia

United States
Weill Medical College of Cornell University
Pfizer; Millennium Pharmaceuticals, Inc.

Terminated

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Pfizer

Completed

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

Healthy

United States
Pfizer

Completed

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

Healthy, Hepatic Insufficiency

United States
Jonsson Comprehensive Cancer Center
Bayer; Translational Research in Oncology-U.S. Inc. (TRIO-US)

Terminated

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Stage I Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | KRAS Gene Mutation | Metastatic Malignant Solid Neoplasm | EGFR Gene Mutation | ERBB2 Gene Amplification | ERBB2 Gene Mutation | EGFR Gene Amplification | ERBB3 Gene Mutation | ERBB4 Gene Mutation

United States
Dana-Farber Cancer Institute
Pfizer

Recruiting

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Pancreatic Cancer | Solid Tumors | Lung Cancer Squamous Cell | Head & Neck Cancer

United States
Washington University School of Medicine
Pfizer

Completed

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Carcinoma, Squamous Cell of Head and Neck

United States
Alliance Foundation Trials, LLC.
Pfizer

Active, not recruiting

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

B Cell Lymphoma | Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Renal Cell Carcinoma

United States, Australia, Israel
Pfizer

Completed

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

Healthy

United States
Mahidol University

Active, not recruiting

Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma

Head and Neck Cancer | Locally Advanced

Thailand
Pfizer

Completed

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine
National Cancer Institute (NCI)

Recruiting

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Malignant Solid Neoplasm | Stage IV Pancreatic Cancer AJCC v8 | Pancreatic Carcinoma | Stage IV Ovarian Cancer AJCC v8 | Ovarian Low Grade Serous Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI); Pfizer; National Institutes of Health (NIH)

Completed

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Sarcoma | Head and Neck Cancer | Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Colorectal Cancer | Ovarian Cancer | Bladder Cancer | Stage IV Non-Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer and other conditions

United States

Search clinical trials for: PD-0332991

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations